Robert Driscoll
Stock Analyst at Wedbush
(3.49)
# 2,293
Out of 5,090 analysts
400
Total ratings
37.7%
Success rate
3.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GERN Geron | Reiterated: Buy | $6 → $5 | $0.8944 | +459.03% | 15 | Oct 29, 2026 | |
| REPL Replimune Group | Reiterated: Buy | $19 | $17.61 | +7.89% | 23 | Oct 29, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $60 | $31.96 | +87.73% | 28 | Oct 26, 2026 | |
| AVTX Avalo Therapeutics | Reiterated: Buy | $34 → $22 | $7.17 | +206.83% | 5 | Oct 23, 2026 | |
| ARVN Arvinas | Reiterated: Hold | $12 | $7.86 | +52.67% | 28 | Oct 8, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $42 | $15.03 | +179.44% | 22 | Oct 7, 2026 | |
| FHTX Foghorn Therapeutics | Downgraded: Hold | $10 → $2 | $2.08 | -3.85% | 16 | Oct 2, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterated: Buy | $37 → $27 | $10.76 | +150.93% | 13 | Oct 2, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Buy | $43 | $18.19 | +136.39% | 26 | Sep 30, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | $25 → $28 | $3.42 | +718.71% | 13 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1 | $0.7865 | +27.15% | 5 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $4.22 | +610.90% | 7 | Sep 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $13.48 | +100.30% | 7 | Sep 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 | $21.07 | +151.54% | 17 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $201 → $225 | $191.31 | +17.61% | 26 | Aug 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $1.81 | +231.49% | 3 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 → $39 | $22.72 | +71.65% | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $1.78 | +686.52% | 15 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $10.26 | +250.88% | 31 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $2.34 | +370.09% | 18 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $64.68 | +23.69% | 4 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.4846 | +1,138.13% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $7 → $5 | $5.31 | -5.84% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $17.47 | +106.07% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.9861 | +1.41% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.96 | n/a | 13 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $4.56 | n/a | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1.6 | - | n/a | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $170.68 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $4.21 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $10.03 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
Geron
Oct 29, 2026
Reiterated: Buy
Price Target: $6 → $5
Current: $0.8944
Upside: +459.03%
Replimune Group
Oct 29, 2026
Reiterated: Buy
Price Target: $19
Current: $17.61
Upside: +7.89%
IDEAYA Biosciences
Oct 26, 2026
Reiterated: Buy
Price Target: $60
Current: $31.96
Upside: +87.73%
Avalo Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $34 → $22
Current: $7.17
Upside: +206.83%
Arvinas
Oct 8, 2026
Reiterated: Hold
Price Target: $12
Current: $7.86
Upside: +52.67%
Cullinan Therapeutics
Oct 7, 2026
Reiterated: Buy
Price Target: $42
Current: $15.03
Upside: +179.44%
Foghorn Therapeutics
Oct 2, 2026
Downgraded: Hold
Price Target: $10 → $2
Current: $2.08
Upside: -3.85%
Monte Rosa Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $37 → $27
Current: $10.76
Upside: +150.93%
Arcus Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $43
Current: $18.19
Upside: +136.39%
Adicet Bio
Sep 29, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $3.42
Upside: +718.71%
Sep 23, 2026
Downgraded: Hold
Price Target: $8 → $1
Current: $0.7865
Upside: +27.15%
Sep 15, 2026
Reiterated: Buy
Price Target: $30
Current: $4.22
Upside: +610.90%
Sep 14, 2026
Reiterated: Buy
Price Target: $27
Current: $13.48
Upside: +100.30%
Sep 11, 2026
Reiterated: Buy
Price Target: $53
Current: $21.07
Upside: +151.54%
Aug 27, 2026
Reiterated: Buy
Price Target: $201 → $225
Current: $191.31
Upside: +17.61%
Aug 14, 2026
Reiterated: Buy
Price Target: $6
Current: $1.81
Upside: +231.49%
Aug 12, 2026
Reiterated: Buy
Price Target: $33 → $39
Current: $22.72
Upside: +71.65%
Aug 6, 2026
Reiterated: Buy
Price Target: $14
Current: $1.78
Upside: +686.52%
Jul 28, 2026
Reiterated: Buy
Price Target: $36
Current: $10.26
Upside: +250.88%
Jun 4, 2026
Reiterated: Buy
Price Target: $11
Current: $2.34
Upside: +370.09%
May 18, 2026
Reiterated: Buy
Price Target: $80
Current: $64.68
Upside: +23.69%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.4846
Upside: +1,138.13%
May 12, 2026
Reiterated: Sell
Price Target: $7 → $5
Current: $5.31
Upside: -5.84%
May 8, 2026
Reiterated: Buy
Price Target: $45 → $36
Current: $17.47
Upside: +106.07%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.9861
Upside: +1.41%
Aug 7, 2025
Reiterated: Hold
Price Target: $4
Current: $1.96
Upside: n/a
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $4.56
Upside: n/a
Mar 20, 2025
Downgraded: Hold
Price Target: $8 → $1.6
Current: -
Upside: n/a
Nov 19, 2021
Reiterated: Buy
Price Target: $67
Current: $170.68
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $7 → $6
Current: $4.21
Upside: n/a
Oct 5, 2020
Reiterated: Buy
Price Target: $8
Current: $10.03
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a